Skip to content

Cortical inhibition and cortical plasticity in individuals with Neurofibromatosis type 1 using transcranial magnetic stimulation

Cortical inhibition and cortical plasticity in individuals with Neurofibromatosis type 1 using transcranial magnetic stimulation - Inhibition and plasticity in NF1

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON45482
Enrollment
62
Registered
2017-06-14
Start date
2018-02-17
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurofibromatosis type 1 Von Recklinghausen disease

Interventions

Inhibition

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Age 18 - 55 years at inclusion - Oral and written informed consent - Right-handed - NF1 patients with a clinically confirmed diagnosis

Exclusion criteria

Exclusion criteria: - Pregnancy - Not passing the Rossi safety check-list for undergoing a TMS-measurement (Rossi et al., 2009) - Segmental NF1 - Psychoactive agents

Design outcomes

Primary

MeasureTime frame
- Cortical inhibition as reflected by SICI using a conditioning pulse with 60%RMT intensity - Cortical plasticity as reflected by iTBS induced increase of MEP*s over the time course of 20 minutes after plasticity induction.

Secondary

MeasureTime frame
- To determine the difference in motor skill learning between NF1 patients and unaffected controls. - To determine the correlation between cortical inhibition and motor skill learning - To determine the correlation between cortical plasticity and motor skill learning - To determine the correlation between cortical inhibition and cortical plasticity - To determine whether there is a difference in cortical inhibition as measured by the SICI (80%) TMS paradigm between adults with NF1 and unaffected controls - To determine whether there is a difference in cortical inhibition measured by the CSP TMS paradigm between adults with NF1 and unaffected controls.

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)